<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">OTO</journal-id>
<journal-id journal-id-type="hwp">spoto</journal-id>
<journal-title>Otolaryngology–Head and Neck Surgery</journal-title>
<issn pub-type="ppub">0194-5998</issn>
<issn pub-type="epub">1097-6817</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0194599812473237</article-id>
<article-id pub-id-type="publisher-id">10.1177_0194599812473237</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Head and Neck Surgery</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Intralesional Injection versus Mouth Rinse of Triamcinolone Acetonide in Oral Lichen Planus</article-title>
<subtitle>A Randomized Controlled Study</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Lee</surname><given-names>Young Chan</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0194599812473237">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Shin</surname><given-names>Seung Youp</given-names></name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-0194599812473237">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kim</surname><given-names>Sung Wan</given-names></name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-0194599812473237">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Eun</surname><given-names>Young Gyu</given-names></name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-0194599812473237">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0194599812473237"><label>1</label>Department of Otolaryngology–Head and Neck Surgery, Kyung Hee University School of Medicine, Seoul, Korea</aff>
<author-notes>
<corresp id="corresp1-0194599812473237">Young Gyu Eun, MD, PhD, Department of Otolaryngology–Head and Neck Surgery, Kyung Hee University Medical Center, #1 Hoegi-dong, dongdaemun-gu Seoul 130-702, Korea Email: <email>ygeun@khu.ac.kr</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2013</year>
</pub-date>
<volume>148</volume>
<issue>3</issue>
<fpage>443</fpage>
<lpage>449</lpage>
<history>
<date date-type="received">
<day>16</day>
<month>9</month>
<year>2012</year>
</date>
<date date-type="rev-recd">
<day>6</day>
<month>11</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>11</day>
<month>12</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© American Academy of Otolaryngology—Head and Neck Surgery Foundation 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="society">Official journal of the American Academy of Otolaryngology–Head and Neck Surgery Foundation</copyright-holder>
</permissions>
<abstract>
<sec id="section1-0194599812473237">
<title>Objective</title>
<p>To compare the efficacy, relapse, and adverse effects between intralesional injection and mouth rinse of triamcinolone acetonide (TA) in patients with oral lichen planus (OLP).</p>
</sec>
<sec id="section2-0194599812473237">
<title>Study Design</title>
<p>A randomized controlled study.</p>
</sec>
<sec id="section3-0194599812473237">
<title>Setting</title>
<p>College medical center.</p>
</sec>
<sec id="section4-0194599812473237">
<title>Subjects and Methods</title>
<p>Forty consecutive patients, who had been diagnosed with OLP, were recruited. Participants were randomly divided into 2 groups using intralesional injection or mouth rinse of TA. The severity of pain and burning sensation on a 10-cm visual analog scale (VAS) and the Oral Health Impact Profile–14 (OHIP-14) were assessed at weeks 0, 1, 2, 3, 4, and 6. The signs of OLP were quantified using a special scoring system for OLP. The rate of relapse and the adverse effects were compared between both groups.</p>
</sec>
<sec id="section5-0194599812473237">
<title>Results</title>
<p>The VAS scores for pain and burning mouth sensation and objective scoring for OLP were significantly improved at 1, 2, 3, 4, and 6 weeks in both groups. The changes in the VAS for burning mouth sensation, OHIP-14, and objective scoring for OLP were similar between both groups. The change in the VAS for pain from baseline to week 1 in the intralesional injection group was significantly higher than in the mouth rinse group. The rate of adverse effects was significantly higher in the mouth rinse group than in the intralesional injection group (44.4% vs 5.0%).</p>
</sec>
<sec id="section6-0194599812473237">
<title>Conclusion</title>
<p>The efficacies of both treatments were similar. The rate of adverse effects was significantly lower for intralesional injection of TA than mouth rinse of TA.</p>
</sec>
</abstract>
<kwd-group>
<kwd>lichen planus</kwd>
<kwd>intralesional injection</kwd>
<kwd>triamcinolone acetonide</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Oral lichen planus (OLP) is a common chronic inflammatory disease of the oral mucosa and skin related to the immunopathogenesis involving T-cell–mediated cytotoxicity.<sup><xref ref-type="bibr" rid="bibr1-0194599812473237">1</xref></sup> The clinical course of cutaneous lichen planus is often mild and resolves within 2 years, but mucosal lichen planus tends to have a more chronic course and is frequently exacerbated with pain and burning sensations followed by considerable loss of quality of life.<sup><xref ref-type="bibr" rid="bibr2-0194599812473237">2</xref></sup></p>
<p>Although there are multiple treatment options for OLP, corticosteroids are helpful in the management of OLP because of their anti-inflammatory effect and anti-immunologic properties, but their prolonged use should be avoided because of the associated adverse effects.<sup><xref ref-type="bibr" rid="bibr3-0194599812473237">3</xref><xref ref-type="bibr" rid="bibr4-0194599812473237"/>-<xref ref-type="bibr" rid="bibr5-0194599812473237">5</xref></sup> Recently, topical corticosteroids have been considered the first-choice agent for the treatment of OLP.<sup><xref ref-type="bibr" rid="bibr6-0194599812473237">6</xref></sup> However, it is not clear which steroid formulation, concentration, or dosage regimen describes the “standard of care.” There is no evidence regarding the efficacy of the different available galenic formulations of topical corticosteroids.</p>
<p>The objective of this study was to compare the efficacy, relapse, and adverse effects between intralesional injection and mouth rinse of triamcinolone acetonide (TA) in patients with OLP.</p>
<sec id="section7-0194599812473237" sec-type="methods">
<title>Subjects and Methods</title>
<sec id="section8-0194599812473237">
<title>Participants and Study Design</title>
<p>This study was a prospective randomized study involving patients with OLP. Forty consecutive patients, who had been diagnosed with OLP by clinical and histopathologic examination, were recruited. The exclusion criteria were as follows: persons younger than 18 years; a history of topical therapy for OLP in the past 2 weeks or systemic therapy in the past 4 weeks; the presence of skin and/or genital lesions; histopathologic signs of dysplasia; treatment with drugs that may induce lichenoid reactions; a history of corticosteroid allergy; patients with chronic liver disease, immune system dysfunction, or hematological diseases; and pregnancy and lactation. This study was approved by Institutional Review Board of Kyung Hee University Hospital.</p>
</sec>
<sec id="section9-0194599812473237">
<title>Intervention and Outcome Assessment</title>
<p>Twenty patients were instructed to use TA 0.4% mouth rinse (Han All bio Pharma, Seoul, Korea) 3 times daily for 6 weeks. The patient kept the mouth rinse in his or her mouth for 5 minutes and then spat it out and could not eat or drink anything for 30 minutes. The other 20 patients had intralesional injection of 0.5 mL TA (40 mg/mL; Han All bio Pharma). The injection was carried out once a week for the first 4 weeks, and 1 more injection was given after 2 weeks. The injection was placed directly into the subepithelial connective tissue just underlying the lesion adjacent to normal mucosa. The patients were asked not to eat, drink, or smoke for at least 30 minutes after each application.</p>
<p>During the treatments, the patients were assessed at weeks 0, 1, 2, 3, 4, and 6 by the clinician, who did not know the patients’ allocated groups. Patients ranked the severity of pain and burning sensation on a 10-cm visual analog scale (VAS).<sup><xref ref-type="bibr" rid="bibr7-0194599812473237">7</xref></sup> Moreover, the patient’s quality of life was measured with the Oral Health Impact Profile–14 (OHIP-14).<sup><xref ref-type="bibr" rid="bibr8-0194599812473237">8</xref></sup> The OHIP-14 is a self-administered questionnaire that evaluates quality of life using 14 items to measure 7 dimensions: functional limitation, physical pain, psychological discomfort, physical disability, psychological disability, social disability, and handicap. Each dimension is measured by 2 questions. Subjects were asked how often they had had negative impacts in these dimensions during the preceding 1 month. Responses to the questions were recorded using a 5-point Likert scale: 0, <italic>never;</italic> 1, <italic>hardly ever;</italic> 2, <italic>occasionally;</italic> 3, <italic>fairly often;</italic> and 4, <italic>very often</italic>. The overall score for the OHIP-14 was achieved by summing all responses (range, 0-56 points).<sup><xref ref-type="bibr" rid="bibr9-0194599812473237">9</xref></sup></p>
<p>Signs of OLP were quantified using a special scoring system for OLP by Escudier et al.<sup><xref ref-type="bibr" rid="bibr10-0194599812473237">10</xref></sup> The measured score was founded on the extent of the lesion and disease severity at each site. The oral cavity was divided into 17 sites (<xref ref-type="table" rid="table1-0194599812473237"><bold>Table 1</bold></xref>), and criterion-based numerical scores for each site were given. The variables were the extent of site involvement (site score) and the disease severity of the lesion at each site (activity score), and a pain score was included. Pain was self-evaluated by the patient on a scale of 0 to 10 over the previous 2 weeks. Using this special scoring system, the maximum score for sites was 24, disease activity was 72, and pain was 10 (combined score ranged from 0-106) (<xref ref-type="table" rid="table1-0194599812473237"><bold>Table 1</bold></xref>). All patients received a 1-year follow-up for relapse of disease.</p>
<table-wrap id="table1-0194599812473237" position="float">
<label>Table 1.</label>
<caption>
<p>Scoring Methodology Showing Sites Examined, Criteria Used for Numerical Scores and Maximum Scores Possible, and Clinical Extent of Each Site</p>
</caption>
<graphic alternate-form-of="table1-0194599812473237" xlink:href="10.1177_0194599812473237-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Site</th>
<th align="center">Site Score (a)</th>
<th align="center">Severity Score (b)</th>
<th align="center">Activity Score (a × b)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outer lips</td>
<td>0 or 1</td>
<td>0-3</td>
<td>0-3</td>
</tr>
<tr>
<td>Inner lips</td>
<td>0 or 1</td>
<td>0-3</td>
<td>0-3</td>
</tr>
<tr>
<td>Left buccal mucosa</td>
<td>0, 1, or 2</td>
<td>0-3</td>
<td>0-6</td>
</tr>
<tr>
<td>Right buccal mucosa</td>
<td>0, 1, or 2</td>
<td>0-3</td>
<td>0-6</td>
</tr>
<tr>
<td>Gingiva</td>
<td>0, 1, or 2</td>
<td/>
<td/>
</tr>
<tr>
<td> Lower right (distal)</td>
<td>0 or 1</td>
<td>0-3</td>
<td>0-3</td>
</tr>
<tr>
<td> Lower central</td>
<td>0 or 1</td>
<td>0-3</td>
<td>0-3</td>
</tr>
<tr>
<td> Lower left (distal)</td>
<td>0 or 1</td>
<td>0-3</td>
<td>0-3</td>
</tr>
<tr>
<td> Upper left (distal)</td>
<td>0 or 1</td>
<td>0-3</td>
<td>0-3</td>
</tr>
<tr>
<td> Upper central</td>
<td>0 or 1</td>
<td>0-3</td>
<td>0-3</td>
</tr>
<tr>
<td> Upper right (distal)</td>
<td>0 or 1</td>
<td>0-3</td>
<td>0-3</td>
</tr>
<tr>
<td>Dorsum of tongue</td>
<td>0, 1, or 2</td>
<td>0-3</td>
<td>0-6</td>
</tr>
<tr>
<td>Right lateral tongue</td>
<td>0 or 1</td>
<td>0-3</td>
<td>0-3</td>
</tr>
<tr>
<td>Left lateral tongue</td>
<td>0 or 1</td>
<td>0-3</td>
<td>0-3</td>
</tr>
<tr>
<td>Floor of mouth</td>
<td>0, 1, or 2</td>
<td>0-3</td>
<td>0-6</td>
</tr>
<tr>
<td>Hard palate</td>
<td>0, 1, or 2</td>
<td>0-3</td>
<td>0-6</td>
</tr>
<tr>
<td>Soft palate</td>
<td>0, 1, or 2</td>
<td>0-3</td>
<td>0-6</td>
</tr>
<tr>
<td>Oropharynx</td>
<td>0, 1, or 2</td>
<td>0-3</td>
<td>0-6</td>
</tr>
<tr>
<td>Maximum score</td>
<td>24</td>
<td/>
<td>72</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0194599812473237">
<p>Site score: 0, no detectable lesion present; 1, evidence of lichen planus seen; 2, &gt;50% of buccal mucosa, dorsum of tongue, floor of mouth, hard palate, soft palate, or oropharynx affected. Severity score: 0, keratosis only; 1, keratosis with mild erythema (&lt;3 mm from gingival margins); 2, marked erythema (eg, full thickness of gingivae, extensive with atrophy or edema on nonkeratinized mucosa); 3, ulceration present. Pain score: on a scale of 0 to 10, how painful has the lichen planus been over the past 2 weeks? Reproduced by permission from Escudier et al.<sup><xref ref-type="bibr" rid="bibr10-0194599812473237">10</xref></sup></p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section10-0194599812473237">
<title>Adverse Reaction</title>
<p>If the subject experienced any adverse event, the adverse event was recorded and the subject was kept under observation. If the adverse reaction was too serious, treatment was discontinued and the subject was referred to a physician from outside the research group for care. Oral candidiasis was recognized by clinical findings such as a white plaque, which could be scraped off, and red patches, both of which underwent culture testing for confirming candidiasis.</p>
</sec>
<sec id="section11-0194599812473237">
<title>Outcome Measures</title>
<p>The primary outcome measure was change in VAS, OHIP-14, and objective scores at 1, 2, 3, 4, and 6 weeks (at the end of the treatment course) from baseline. The secondary outcome measures were adverse events and relapse rate.</p>
</sec>
<sec id="section12-0194599812473237">
<title>Randomization</title>
<p>Participants were randomly divided into 2 groups that received either an intralesional injection or a mouth rinse of TA according to a list made by block randomization.</p>
</sec>
<sec id="section13-0194599812473237">
<title>Statistical Analysis</title>
<p>Data were expressed as mean ± standard deviation (SD). The parameters after treatment in each group were compared using the paired <italic>t</italic> test. The changes in parameters between both groups were compared using an independent <italic>t</italic> test. The relapse rate and rate of adverse effects were compared with the χ<sup>2</sup> test or Fisher exact test. Statistical significance was accepted at <italic>P</italic> &lt; .05. All statistical analyses were performed using SPSS for Windows, version 18.0 (SPSS, Inc, an IBM Company, Chicago, Illinois).</p>
</sec>
</sec>
<sec id="section14-0194599812473237" sec-type="results">
<title>Results</title>
<p>Of the 40 patients enrolled in the study, 2 patients in the mouth rinse group did not complete the study because they did not return for their appointments (<xref ref-type="fig" rid="fig1-0194599812473237"><bold>Figure 1</bold></xref>). No reasons were given. The demographic profile and clinical characteristics of patients in both groups appear in <xref ref-type="table" rid="table1-0194599812473237"><bold>Table 1</bold></xref>. There were no significant differences between the 2 groups with regard to age, sex, or clinical and symptomatic characteristics at baseline (<xref ref-type="table" rid="table2-0194599812473237"><bold>Table 2</bold></xref>). The VAS scores for pain were significantly improved at 1, 2, 3, 4, and 6 weeks in both groups.</p>
<fig id="fig1-0194599812473237" position="float">
<label>Figure 1.</label>
<caption>
<p>Flow diagram of participants. TA, triamcinolone acetonide.</p>
</caption>
<graphic xlink:href="10.1177_0194599812473237-fig1.tif"/>
</fig>
<table-wrap id="table2-0194599812473237" position="float">
<label>Table 2.</label>
<caption>
<p>Demographic Profile and Clinical Characteristics of Patients in Both Groups</p>
</caption>
<graphic alternate-form-of="table2-0194599812473237" xlink:href="10.1177_0194599812473237-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center">Mouth Rinse Group</th>
<th align="center">Intralesional Injection Group</th>
<th align="center"><italic>P</italic> Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients</td>
<td>18</td>
<td>20</td>
<td/>
</tr>
<tr>
<td>Age, y, mean ± SD</td>
<td>56.6 ± 11.7</td>
<td>57.1 ± 6.6</td>
<td>.844</td>
</tr>
<tr>
<td>Male/female</td>
<td>11/7</td>
<td>9/11</td>
<td>.352</td>
</tr>
<tr>
<td>Pain at baseline (VAS), mean ± SD</td>
<td>3.6 ± 2.1</td>
<td>4.6 ± 3.0</td>
<td>.236</td>
</tr>
<tr>
<td>Burning mouth sensation at baseline (VAS), mean ± SD</td>
<td>3.7 ± 3.1</td>
<td>4.4 ± 3.2</td>
<td>.530</td>
</tr>
<tr>
<td>OHIP-14 at baseline, mean ± SD</td>
<td>16.5 ± 10.6</td>
<td>20.5 ± 13.5</td>
<td>.249</td>
</tr>
<tr>
<td>Objective scoring at baseline, mean ± SD</td>
<td>9.8 ± 4.6</td>
<td>10.0 ± 4.2</td>
<td>.891</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0194599812473237">
<p>Abbreviations: OHIP-14, Oral Health Impact Profile–14; VAS, visual analog scale.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The change in the VAS for pain from baseline to week 1 in the intralesional injection group was significantly higher than in the mouth rinse group. However, the changes in the VAS for pain from baseline to weeks 2, 3, 4, and 6 were not significantly different between both groups (<xref ref-type="table" rid="table3-0194599812473237"><bold>Table 3</bold></xref>). The VAS scores for burning mouth sensation, OHIP-14, and objective scoring for OLP were significantly improved at 1, 2, 3, 4, and 6 weeks in both groups. The changes in the VAS for burning mouth sensation, OHIP-14, and objective scoring for OLP were similar from baseline to weeks 1, 2, 3, 4, and 6 between both groups (<xref ref-type="table" rid="table4-0194599812473237"><bold>Tables 4</bold></xref><xref ref-type="table" rid="table5-0194599812473237"/>-<xref ref-type="table" rid="table6-0194599812473237"><bold>6</bold></xref> and <xref ref-type="fig" rid="fig2-0194599812473237"><bold>Figure 2</bold></xref>).</p>
<table-wrap id="table3-0194599812473237" position="float">
<label>Table 3.</label>
<caption>
<p>Comparison of the Change in the VAS for Pain between the Mouth Rinse Group and the Intralesional Injection Group</p>
</caption>
<graphic alternate-form-of="table3-0194599812473237" xlink:href="10.1177_0194599812473237-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="2">MR Group<hr/></th>
<th align="center" colspan="2">ILI Group<hr/></th>
<th align="center" colspan="3">Change<sup><xref ref-type="table-fn" rid="table-fn4-0194599812473237">a</xref></sup><hr/></th>
</tr>
<tr>
<th/>
<th align="center">Mean ± SD</th>
<th align="center"><italic>P</italic> Value</th>
<th align="center">Mean ± SD</th>
<th align="center"><italic>P</italic> Value</th>
<th align="center">MR Group</th>
<th align="center">ILI Group</th>
<th align="center"><italic>P</italic> Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>3.6 ± 2.1</td>
<td/>
<td>4.6 ± 3.0</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>1 week</td>
<td>2.3 ± 2.2</td>
<td>.001</td>
<td>3.3 ± 3.1</td>
<td>.015</td>
<td>–1.3 ± 1.4</td>
<td>–1.4 ± 2.3</td>
<td>.042</td>
</tr>
<tr>
<td>2 weeks</td>
<td>2.0 ± 2.2</td>
<td>&lt;.01</td>
<td>2.4 ± 1.7</td>
<td>&lt;.01</td>
<td>–1.6 ± 1.4</td>
<td>–2.2 ± 2.3</td>
<td>.589</td>
</tr>
<tr>
<td>3 weeks</td>
<td>1.6 ± 1.7</td>
<td>&lt;.01</td>
<td>2.2 ± 1.7</td>
<td>.001</td>
<td>–2.1 ± 2.1</td>
<td>–2.4 ± 2.7</td>
<td>.314</td>
</tr>
<tr>
<td>4 weeks</td>
<td>1.3 ± 1.7</td>
<td>&lt;.01</td>
<td>2.0 ± 1.7</td>
<td>&lt;.01</td>
<td>–2.5 ± 1.8</td>
<td>–2.6 ± 2.6</td>
<td>.125</td>
</tr>
<tr>
<td>6 weeks</td>
<td>1.3 ± 1.7</td>
<td>&lt;.01</td>
<td>2.1 ± 2.0</td>
<td>.002</td>
<td>–2.4 ± 1.9</td>
<td>–2.7 ± 2.9</td>
<td>.231</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0194599812473237">
<p>Abbreviations: ILI, intralesional injection; MR, mouth rinse; VAS, visual analog scale.</p>
</fn>
<fn id="table-fn4-0194599812473237">
<label>a</label>
<p>The change in the VAS for pain from baseline to 1, 2, 3, 4, and 6 weeks.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table4-0194599812473237" position="float">
<label>Table 4.</label>
<caption>
<p>Comparison of the Change in the VAS for Burning Mouth Sensation between the Mouth Rinse Group and the Intralesional Injection Group</p>
</caption>
<graphic alternate-form-of="table4-0194599812473237" xlink:href="10.1177_0194599812473237-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="2">MR Group<hr/></th>
<th align="center" colspan="2">ILI Group<hr/></th>
<th align="center" colspan="3">Change<sup><xref ref-type="table-fn" rid="table-fn6-0194599812473237">a</xref></sup><hr/></th>
</tr>
<tr>
<th/>
<th align="center">Mean ± SD</th>
<th align="center"><italic>P</italic> Value</th>
<th align="center">Mean ± SD</th>
<th align="center"><italic>P</italic> Value</th>
<th align="center">MR Group</th>
<th align="center">ILI Group</th>
<th align="center"><italic>P</italic> Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>3.7 ± 3.1</td>
<td/>
<td>4.4 ± 3.2</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>1 week</td>
<td>2.2 ± 2.7</td>
<td>.004</td>
<td>2.7 ± 2.8</td>
<td>.002</td>
<td>–1.1 ± 1.6</td>
<td>–1.7 ± 2.1</td>
<td>.434</td>
</tr>
<tr>
<td>2 weeks</td>
<td>1.9 ± 2.8</td>
<td>.013</td>
<td>2.5 ± 2.5</td>
<td>.001</td>
<td>–1.6 ± 3.0</td>
<td>–1.9 ± 2.3</td>
<td>.758</td>
</tr>
<tr>
<td>3 weeks</td>
<td>1.4 ± 2.0</td>
<td>.002</td>
<td>2.0 ± 2.1</td>
<td>&lt;.01</td>
<td>–2.4 ± 3.0</td>
<td>–2.4 ± 2.4</td>
<td>.955</td>
</tr>
<tr>
<td>4 weeks</td>
<td>1.3 ± 2.2</td>
<td>.001</td>
<td>1.8 ± 1.8</td>
<td>&lt;.01</td>
<td>2.6 ± 2.9</td>
<td>–1.9 ± 2.3</td>
<td>.955</td>
</tr>
<tr>
<td>6 weeks</td>
<td>0.6 ± 0.9</td>
<td>.001</td>
<td>1.4 ± 1.6</td>
<td>&lt;.01</td>
<td>–3.4 ± 3.3</td>
<td>–3.0 ± 2.6</td>
<td>.744</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-0194599812473237">
<p>Abbreviations: ILI, intralesional injection; MR, mouth rinse; VAS, visual analog scale.</p>
</fn>
<fn id="table-fn6-0194599812473237">
<label>a</label>
<p>The change in the VAS for burning mouth sensation from baseline to 1, 2, 3, 4, and 6 weeks.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table5-0194599812473237" position="float">
<label>Table 5.</label>
<caption>
<p>Comparison of the Change in the OHIP-14 between the Mouth Rinse Group and the Intralesional Injection Group</p>
</caption>
<graphic alternate-form-of="table5-0194599812473237" xlink:href="10.1177_0194599812473237-table5.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="2">MR Group<hr/></th>
<th align="center" colspan="2">ILI Group<hr/></th>
<th align="center" colspan="3">Change<sup><xref ref-type="table-fn" rid="table-fn8-0194599812473237">a</xref></sup><hr/></th>
</tr>
<tr>
<th/>
<th align="center">Mean ± SD</th>
<th align="center"><italic>P</italic> Value</th>
<th align="center">Mean ± SD</th>
<th align="center"><italic>P</italic> Value</th>
<th align="center">MR Group</th>
<th align="center">ILI Group</th>
<th align="center"><italic>P</italic> Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>16.5 ± 10.6</td>
<td/>
<td>20.5 ± 13.5</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>1 week</td>
<td>11.6 ± 12.7</td>
<td>.003</td>
<td>15.1 ± 12.7</td>
<td>.060</td>
<td>–3.9 ± 4.9</td>
<td>–5.4 ± 12.1</td>
<td>.612</td>
</tr>
<tr>
<td>2 weeks</td>
<td>10.1 ± 12.3</td>
<td>.003</td>
<td>11.9 ± 12.5</td>
<td>.007</td>
<td>–5.9 ± 6.6</td>
<td>–8.6 ± 12.8</td>
<td>.422</td>
</tr>
<tr>
<td>3 weeks</td>
<td>8.3 ± 9.1</td>
<td>.002</td>
<td>11.2 ± 11.4</td>
<td>.008</td>
<td>–8.6 ± 11.2</td>
<td>–9.4 ± 14.1</td>
<td>.877</td>
</tr>
<tr>
<td>4 weeks</td>
<td>5.0 ± 4.8</td>
<td>&lt;.01</td>
<td>9.8 ± 12.1</td>
<td>.005</td>
<td>–11.1 ± 11.1</td>
<td>–10.7 ± 14.9</td>
<td>.938</td>
</tr>
<tr>
<td>6 weeks</td>
<td>4.6 ± 5.1</td>
<td>&lt;.01</td>
<td>6.4 ± 6.0</td>
<td>&lt;.01</td>
<td>–11.5 ± 10.8</td>
<td>–14.4 ± 11.3</td>
<td>.459</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn7-0194599812473237">
<p>Abbreviations: ILI, intralesional injection; MR, mouth rinse; OHIP-14, Oral Health Impact Profile–14.</p>
</fn>
<fn id="table-fn8-0194599812473237">
<label>a</label>
<p>The change in the OHIP-14 from baseline to 1, 2, 3, 4, and 6 weeks.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table6-0194599812473237" position="float">
<label>Table 6.</label>
<caption>
<p>Comparison of the Change in the Objective Scoring between the Mouth Rinse Group and the Intralesional Injection Group</p>
</caption>
<graphic alternate-form-of="table6-0194599812473237" xlink:href="10.1177_0194599812473237-table6.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="2">MR Group<hr/></th>
<th align="center" colspan="2">ILI Group<hr/></th>
<th align="center" colspan="3">Change<sup><xref ref-type="table-fn" rid="table-fn10-0194599812473237">a</xref></sup><hr/></th>
</tr>
<tr>
<th/>
<th align="center">Mean ± SD</th>
<th align="center"><italic>P</italic> Value</th>
<th align="center">Mean ± SD</th>
<th align="center"><italic>P</italic> Value</th>
<th align="center">MR Group</th>
<th align="center">ILI Group</th>
<th align="center"><italic>P</italic> Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>9.8 ± 4.6</td>
<td/>
<td>10.0 ± 4.2</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>1 week</td>
<td>5.9 ± 4.0</td>
<td>&lt;.01</td>
<td>7.2 ± 4.3</td>
<td>.001</td>
<td>–3.8 ± 3.3</td>
<td>–2.8 ± 3.1</td>
<td>.340</td>
</tr>
<tr>
<td>2 weeks</td>
<td>4.4 ± 3.6</td>
<td>&lt;.01</td>
<td>4.5 ± 2.7</td>
<td>&lt;.01</td>
<td>–5.4 ± 3.6</td>
<td>–5.5 ± 3.1</td>
<td>.955</td>
</tr>
<tr>
<td>3 weeks</td>
<td>3.3 ± 2.9</td>
<td>&lt;.01</td>
<td>3.9 ± 2.5</td>
<td>&lt;.01</td>
<td>–6.5 ± 4.3</td>
<td>–6.1 ± 3.2</td>
<td>.731</td>
</tr>
<tr>
<td>4 weeks</td>
<td>3.1 ± 2.5</td>
<td>&lt;.01</td>
<td>3.5 ± 2.7</td>
<td>&lt;.01</td>
<td>–6.7 ± 3.9</td>
<td>–6.5 ± 3.8</td>
<td>.844</td>
</tr>
<tr>
<td>6 weeks</td>
<td>2.6 ± 2.6</td>
<td>&lt;.01</td>
<td>2.9 ± 2.9</td>
<td>&lt;.01</td>
<td>–7.2 ± 4.3</td>
<td>–7.1 ± 3.6</td>
<td>.974</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn9-0194599812473237">
<p>Abbreviations: ILI, intralesional injection; MR, mouth rinse; VAS, visual analog scale.</p>
</fn>
<fn id="table-fn10-0194599812473237">
<label>a</label>
<p>The change in the objective scoring from baseline to 1, 2, 3, 4, and 6 weeks.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="fig2-0194599812473237" position="float">
<label>Figure 2.</label>
<caption>
<p>(A, B) Bilateral erosive lesions of the lateral tongue. (C, D) Complete remission following a 6-week treatment with intralesional injection.</p>
</caption>
<graphic xlink:href="10.1177_0194599812473237-fig2.tif"/>
</fig>
<p>All patients received a 1-year follow-up for relapse of disease. Five of 18 (27.8%) patients in the mouth rinse group relapsed and 8 of 20 (40.0%) patients in the intralesional injection group relapsed. The relapse rates between both groups were not significantly different (<italic>P</italic> = .428). Relapses appeared 2 to 52 weeks after the treatment. The mean duration to relapse in the mouth rinse group was 20. 92 ± 17.84 weeks (range, 2-41 weeks). The mean duration to relapse in the intralesional injection group was 32.63 ± 15.84 weeks (range, 5-52 weeks). There was no significant difference in relapse time between the 2 groups (<italic>P</italic> = .241).</p>
<p>Eight (44.4%) patients in the mouth rinse group developed secondary oral candidiasis. One patient (5.0%) in the intralesional injection group developed cushingoid features in the form of edema over the face, which was mild, transient, and reversible. The rate of adverse events was significantly higher in the mouth rinse group than in intralesional injection group (44.4% vs 5.0%, <italic>P</italic> = .007).</p>
</sec>
<sec id="section15-0194599812473237" sec-type="discussion">
<title>Discussion</title>
<p>To our knowledge, this is the first randomized study to compare the different available galenic formulations of topical steroid in patients with OLP. The findings of this study are as follows: (1) mouth rinse and the intralesional injection of TA resulted in a reduction of pain, burning mouth sensation, and objective score for OLP and improved the patient’s quality of life over the 6 weeks. (2) The relapse rate was not different in both formulations. (3) The rate of adverse events was significantly lower in the intralesional injection group than in the mouth rinse group.</p>
<p>Although the etiology of OLP is unknown, it is known that OLP is developed by a cell-mediated immune response with an inflammatory infiltrating cell population composed of T lymphocytes.<sup><xref ref-type="bibr" rid="bibr11-0194599812473237">11</xref><xref ref-type="bibr" rid="bibr12-0194599812473237"/>-<xref ref-type="bibr" rid="bibr13-0194599812473237">13</xref></sup> The pathogenesis of OLP is involved with many factors, such as matrix metalloproteinases, chymase, tryptase, and proinflammatory cytokines.<sup><xref ref-type="bibr" rid="bibr1-0194599812473237">1</xref></sup> Tumor necrosis factor (TNF)–α, which is one of the proinflammatory cytokines, has been proposed to play a role in the pathogenesis and inflammatory process of OLP.<sup><xref ref-type="bibr" rid="bibr14-0194599812473237">14</xref></sup> This immunological abnormality causes hyperkeratosis.<sup><xref ref-type="bibr" rid="bibr15-0194599812473237">15</xref></sup> Triamcinolone is a fluorinated prednisolone derivative, and the 9-a fluoridation results in enhanced anti-inflammatory properties.<sup><xref ref-type="bibr" rid="bibr16-0194599812473237">16</xref>,<xref ref-type="bibr" rid="bibr17-0194599812473237">17</xref></sup> The efficacy of TA treatment in OLP is mainly based on the local anti-inflammatory and anti-immunological effects of suppressing T-cell function.<sup><xref ref-type="bibr" rid="bibr12-0194599812473237">12</xref>,<xref ref-type="bibr" rid="bibr16-0194599812473237">16</xref>,<xref ref-type="bibr" rid="bibr17-0194599812473237">17</xref></sup></p>
<p>An intralesional steroid has been proposed as an effective and simple method with the aim of attaining sufficiently high drug concentrations locally for an enhanced immunosuppressing effect but less systemic toxicity.<sup><xref ref-type="bibr" rid="bibr16-0194599812473237">16</xref>,<xref ref-type="bibr" rid="bibr18-0194599812473237">18</xref></sup> The TA aqueous injectable suspension remains longer at the injection site because it is insoluble.<sup><xref ref-type="bibr" rid="bibr16-0194599812473237">16</xref>,<xref ref-type="bibr" rid="bibr17-0194599812473237">17</xref></sup> Intralesional injection of TA has been known as a successful treatment of oral submucous fibrosis, temporomandibular joint osteoarthrosis, central giant cell granuloma, and cheilitis granulomatosa.<sup><xref ref-type="bibr" rid="bibr19-0194599812473237">19</xref><xref ref-type="bibr" rid="bibr20-0194599812473237"/><xref ref-type="bibr" rid="bibr21-0194599812473237"/><xref ref-type="bibr" rid="bibr22-0194599812473237"/>-<xref ref-type="bibr" rid="bibr23-0194599812473237">23</xref></sup> However, there have been few reports about the intralesional injection of TA in the management of OLP. Xia et al<sup><xref ref-type="bibr" rid="bibr24-0194599812473237">24</xref></sup> reported that the intralesional injection of TA reduced the signs and symptoms in 84.4% of patients with ulcerative OLP. Xiong et al<sup><xref ref-type="bibr" rid="bibr25-0194599812473237">25</xref></sup> reported that the intralesional injection of TA that was used as a positive control showed improvement in 88.0% of patients. However, some authors have been skeptical of the efficacy of this modality because of a lack of evidence of its superiority compared with topical steroids and the pain associated with injections.<sup><xref ref-type="bibr" rid="bibr26-0194599812473237">26</xref></sup> In our results, the intralesional injection of TA improved the VAS score for pain and burning sensation, quality of life of patients (OHIP-14), and objective score for OLP during the 6-week treatment period.</p>
<p>In another study, TA mouthwash was used to compare with Orabase (Bristol-Myers Squibb, Bangkok, Thailand) in the treatment of 20 cases of OLP.<sup><xref ref-type="bibr" rid="bibr27-0194599812473237">27</xref></sup> Ten of 11 patients treated with the mouthwash for 4 weeks showed positive responses. The results indicated that TA mouthwash was well accepted by the OLP patients. Moreover, therapeutic efficacy of TA mouthwash was not significantly different from the commercial paste dosage form in the treatment of OLP in that study. Rhodus et al<sup><xref ref-type="bibr" rid="bibr28-0194599812473237">28</xref></sup> reported that dexamethasone mouthwash significantly decreased the production of proinflammatory cytokines, TNF-α, interleukin (IL)-1α, IL-6, and IL-8 and gave satisfactory clinical outcomes in erosive OLP. Betamethasone mouth rinse significantly reduced painful symptoms as measured by the VAS, improved the quality of life, and reduced the surface area of oral lesions.<sup><xref ref-type="bibr" rid="bibr29-0194599812473237">29</xref></sup> In erosive OLP, clinical outcomes of TA mouth rinse at concentrations of 0.3% or 0.5% were total remission in 80.0% and partial remission in 17.1% at 6 months.<sup><xref ref-type="bibr" rid="bibr30-0194599812473237">30</xref></sup> In our results, TA mouth rinse improved the VAS score for pain and burning sensation, quality of life of patients, and objective score for OLP during the 6-week treatment periods.</p>
<p>In previous studies, any specific topical corticosteroid therapy was more or less effective at improving pain as compared with another type or dose of corticosteroid.<sup><xref ref-type="bibr" rid="bibr31-0194599812473237">31</xref><xref ref-type="bibr" rid="bibr32-0194599812473237"/><xref ref-type="bibr" rid="bibr33-0194599812473237"/><xref ref-type="bibr" rid="bibr34-0194599812473237"/>-<xref ref-type="bibr" rid="bibr35-0194599812473237">35</xref></sup> In our results, the efficacy was not significantly different between mouth rinse and intralesional injection of TA. Our results are consistent with previous studies.</p>
<p>Superpotent topical steroids were reported to cause systemic absorption and adrenal suppression in the treatment of chronic skin diseases.<sup><xref ref-type="bibr" rid="bibr36-0194599812473237">36</xref>,<xref ref-type="bibr" rid="bibr37-0194599812473237">37</xref></sup> However, adrenal suppression has not been found in the long-term use of topical corticosteroids for the treatment of OLP.<sup><xref ref-type="bibr" rid="bibr34-0194599812473237">34</xref>,<xref ref-type="bibr" rid="bibr38-0194599812473237">38</xref>,<xref ref-type="bibr" rid="bibr39-0194599812473237">39</xref></sup> Clobetasol propionate 0.05% mouthwash caused mild adverse effects (moon face and hirsutism) between weeks 4 and 6 of treatment.<sup><xref ref-type="bibr" rid="bibr40-0194599812473237">40</xref></sup> Other minor adverse effects have been associated with fluticasone propionate spray, such as bad taste and smell, nausea, dry mouth, sore throat, swollen mouth, and candidiasis.<sup><xref ref-type="bibr" rid="bibr32-0194599812473237">32</xref></sup> There was a report that fungal infection was found in 11.4% of patients after TA mouth rinse at a concentration of 0.3% or 0.5%.<sup><xref ref-type="bibr" rid="bibr30-0194599812473237">30</xref></sup> In our results, 44.4% of patients in the mouth rinse group developed candidiasis. In a previous report, an intralesional injection of TA caused a tingling or burning sensation at the injection site.<sup><xref ref-type="bibr" rid="bibr25-0194599812473237">25</xref></sup> In another report, no complications were noted with the volume and concentration of TA.<sup><xref ref-type="bibr" rid="bibr24-0194599812473237">24</xref></sup> In our results, cushingoid features had developed and resolved after 2 weeks in only 1 patient. The rate of an adverse effect was significantly higher in the mouth rinse group than in the intralesional injection group.</p>
<p>The major limitation of any therapeutic trial in OLP while evaluating the efficacy of a drug is the lack of objective criteria for assessing the severity and the response to treatment,<sup><xref ref-type="bibr" rid="bibr41-0194599812473237">41</xref></sup> so we used a special scoring system based on the involved lesion, severity of disease, and presence of symptoms by Escudier et al. The scoring systems by Escudier et al provide the disease involvement of each site, individually and on an overall basis, thus yielding a more exact image of the disorder. Another advantage of this scoring system is the usage of disease activity.<sup><xref ref-type="bibr" rid="bibr42-0194599812473237">42</xref></sup> The OLP is known as a dynamic disease. Erosive lesions might aggravate to form ulcers. Ulcers might heal by reepithelialization and change to be erythematous. Also, we used not only the VAS for pain and burning sensation but also the OHIP-14 for a standardized and reliable comparison of the efficacy of treatments. Quality of life has been accepted as a valid and significant indicator of service need and treatment outcomes in public health research and practice. Health-related quality-of-life measures are especially useful for assessing efforts to prevent disabling chronic diseases and evaluating their effectiveness.<sup><xref ref-type="bibr" rid="bibr43-0194599812473237">43</xref></sup> The OHIP is a questionnaire proposed to assess self-reported dysfunction, discomfort, and disability from oral conditions and is founded on a conceptual oral health model designed by Locker et al.<sup><xref ref-type="bibr" rid="bibr43-0194599812473237">43</xref></sup> The OHIP-14 is useful for quantifying levels of impact on well-being in settings where only a limited number of questions can be administered.<sup><xref ref-type="bibr" rid="bibr10-0194599812473237">10</xref></sup></p>
</sec>
<sec id="section16-0194599812473237" sec-type="conclusions">
<title>Conclusion</title>
<p>Both mouth rinse and intralesional injection of TA resulted in a reduction of pain, burning mouth sensation, and objective score for OLP and improved the patient’s quality of life during 6 weeks. The efficacies of both treatments were similar. The rate of adverse effects was significantly lower for the intralesional injection of TA than the mouth rinse of TA.</p>
</sec>
<sec id="section17-0194599812473237">
<title>Author Contributions</title>
<p><bold>Young Chan Lee</bold>, study design, data collection and analysis, writing; <bold>Seung Youp Shin</bold>, study design, data collection and analysis; <bold>Sung Wan Kim</bold>, study design, data collection and analysis; <bold>Young Gyu Eun</bold>, study design, data collection and analysis, supervising the study, writing.</p>
</sec>
<sec id="section18-0194599812473237">
<title>Disclosures</title>
<p><bold>Competing interests:</bold> None.</p>
<p><bold>Sponsorships:</bold> None.</p>
<p><bold>Funding source:</bold> None.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="presented-at">
<p>No sponsorships or competing interests have been disclosed for this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0194599812473237">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lodi</surname><given-names>G</given-names></name>
<name><surname>Scully</surname><given-names>C</given-names></name>
<name><surname>Carrozzo</surname><given-names>M</given-names></name>
<name><surname>Griffiths</surname><given-names>M</given-names></name>
<name><surname>Sugerman</surname><given-names>PB</given-names></name>
<name><surname>Thongprasom</surname><given-names>K</given-names></name>
</person-group>. <article-title>Current controversies in oral lichen planus: report of an international consensus meeting. Part 1. Viral infections and etiopathogenesis</article-title>. <source>Oral Surg Oral Med Oral Pathol Oral Radiol Endod</source>. <year>2005</year>;<volume>100</volume>:<fpage>40</fpage>-<lpage>51</lpage>.</citation>
</ref>
<ref id="bibr2-0194599812473237">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dissemond</surname><given-names>J</given-names></name>
</person-group>. <article-title>Oral lichen planus: an overview</article-title>. <source>J Dermatolog Treat</source>. <year>2004</year>;<volume>15</volume>:<fpage>136</fpage>-<lpage>140</lpage>.</citation>
</ref>
<ref id="bibr3-0194599812473237">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zegarelli</surname><given-names>D</given-names></name>
</person-group>. <article-title>Multimodality steroid therapy of erosive and ulcerative oral lichen planus</article-title>. <source>J Oral Med</source>. <year>1983</year>;<volume>38</volume>:<fpage>127</fpage>.</citation>
</ref>
<ref id="bibr4-0194599812473237">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stoppoloni</surname><given-names>G</given-names></name>
<name><surname>Prisco</surname><given-names>F</given-names></name>
<name><surname>Santinelli</surname><given-names>R</given-names></name>
<name><surname>Sicuranza</surname><given-names>G</given-names></name>
<name><surname>Giordano</surname><given-names>C</given-names></name>
</person-group>. <article-title>Potential hazards of topical steroid therapy</article-title>. <source>Am J Dis Child</source>. <year>1983</year>;<volume>137</volume>:<fpage>1130</fpage>-<lpage>1131</lpage>.</citation>
</ref>
<ref id="bibr5-0194599812473237">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Passeron</surname><given-names>T</given-names></name>
<name><surname>Lacour</surname><given-names>JP</given-names></name>
<name><surname>Fontas</surname><given-names>E</given-names></name>
<name><surname>Ortonne</surname><given-names>JP</given-names></name>
</person-group>. <article-title>Treatment of oral erosive lichen planus with 1% pimecrolimus cream: a double-blind, randomized, prospective trial with measurement of pimecrolimus levels in the blood</article-title>. <source>Arch Dermatol</source>. <year>2007</year>;<volume>143</volume>:<fpage>472</fpage>.</citation>
</ref>
<ref id="bibr6-0194599812473237">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lodi</surname><given-names>G</given-names></name>
<name><surname>Scully</surname><given-names>C</given-names></name>
<name><surname>Carrozzo</surname><given-names>M</given-names></name>
<name><surname>Griffiths</surname><given-names>M</given-names></name>
<name><surname>Sugerman</surname><given-names>PB</given-names></name>
<name><surname>Thongprasom</surname><given-names>K</given-names></name>
</person-group>. <article-title>Current controversies in oral lichen planus: report of an international consensus meeting. Part 2. Clinical management and malignant transformation</article-title>. <source>Oral Surg Oral Med Oral Pathol Oral Radiol Endod</source>. <year>2005</year>;<volume>100</volume>:<fpage>164</fpage>-<lpage>178</lpage>.</citation>
</ref>
<ref id="bibr7-0194599812473237">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Scott</surname><given-names>J</given-names></name>
<name><surname>Huskisson</surname><given-names>E</given-names></name>
</person-group>. <article-title>Graphic representation of pain</article-title>. <source>Pain</source>. <year>1976</year>;<volume>2</volume>:<fpage>175</fpage>-<lpage>184</lpage>.</citation>
</ref>
<ref id="bibr8-0194599812473237">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Slade</surname><given-names>GD</given-names></name>
</person-group>. <article-title>Derivation and validation of a short-form oral health impact profile</article-title>. <source>Community Dent Oral Epidemiol</source>. <year>1997</year>;<volume>25</volume>:<fpage>284</fpage>-<lpage>290</lpage>.</citation>
</ref>
<ref id="bibr9-0194599812473237">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Slade</surname><given-names>GD</given-names></name>
<name><surname>Nuttall</surname><given-names>N</given-names></name>
<name><surname>Sanders</surname><given-names>AE</given-names></name>
<name><surname>Steele</surname><given-names>JG</given-names></name>
<name><surname>Allen</surname><given-names>PF</given-names></name>
<name><surname>Lahti</surname><given-names>S</given-names></name>
</person-group>. <article-title>Impacts of oral disorders in the United Kingdom and Australia</article-title>. <source>Br Dent J</source>. <year>2005</year>;<volume>198</volume>:<fpage>489</fpage>-<lpage>493</lpage>.</citation>
</ref>
<ref id="bibr10-0194599812473237">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Escudier</surname><given-names>M</given-names></name>
<name><surname>Ahmed</surname><given-names>N</given-names></name>
<name><surname>Shirlaw</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>A scoring system for mucosal disease severity with special reference to oral lichen planus</article-title>. <source>Br J Dermatol</source>. <year>2007</year>;<volume>157</volume>:<fpage>765</fpage>-<lpage>770</lpage>.</citation>
</ref>
<ref id="bibr11-0194599812473237">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>Z</given-names></name>
<name><surname>Savage</surname><given-names>N</given-names></name>
<name><surname>Sugerman</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>Mast cell/T cell interactions in oral lichen planus</article-title>. <source>J Oral Pathol Med</source>. <year>2002</year>;<volume>31</volume>:<fpage>189</fpage>-<lpage>195</lpage>.</citation>
</ref>
<ref id="bibr12-0194599812473237">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kawamura</surname><given-names>E</given-names></name>
<name><surname>Nakamura</surname><given-names>S</given-names></name>
<name><surname>Sasaki</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Accumulation of oligoclonal T cells in the infiltrating lymphocytes in oral lichen planus</article-title>. <source>J Oral Pathol Med</source>. <year>2003</year>;<volume>32</volume>:<fpage>282</fpage>-<lpage>289</lpage>.</citation>
</ref>
<ref id="bibr13-0194599812473237">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dorrego</surname><given-names>MV</given-names></name>
<name><surname>Correnti</surname><given-names>M</given-names></name>
<name><surname>Delgado</surname><given-names>R</given-names></name>
<name><surname>Tapia</surname><given-names>FJ</given-names></name>
</person-group>. <article-title>Oral lichen planus: immunohistology of mucosal lesions</article-title>. <source>J Oral Pathol Med</source>. <year>2002</year>;<volume>31</volume>:<fpage>410</fpage>-<lpage>414</lpage>.</citation>
</ref>
<ref id="bibr14-0194599812473237">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thongprasom</surname><given-names>K</given-names></name>
<name><surname>Dhanuthai</surname><given-names>K</given-names></name>
<name><surname>Sarideechaigul</surname><given-names>W</given-names></name>
<name><surname>Chaiyarit</surname><given-names>P</given-names></name>
<name><surname>Chaimusig</surname><given-names>M</given-names></name>
</person-group>. <article-title>Expression of TNF-α in oral lichen planus treated with fluocinolone acetonide 0.1%</article-title>. <source>J Oral Pathol Med</source>. <year>2006</year>;<volume>35</volume>:<fpage>161</fpage>-<lpage>166</lpage>.</citation>
</ref>
<ref id="bibr15-0194599812473237">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eisenberg</surname><given-names>E</given-names></name>
</person-group>. <article-title>Oral lichen planus: a benign lesion</article-title>. <source>J Oral Maxillofac Surg</source>. <year>2000</year>;<volume>58</volume>:<fpage>1278</fpage>-<lpage>1285</lpage>.</citation>
</ref>
<ref id="bibr16-0194599812473237">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kumar</surname><given-names>S</given-names></name>
<name><surname>Singh</surname><given-names>RJ</given-names></name>
<name><surname>Reed</surname><given-names>AM</given-names></name>
<name><surname>Lteif</surname><given-names>AN</given-names></name>
</person-group>. <article-title>Cushing’s syndrome after intra-articular and intradermal administration of triamcinolone acetonide in three pediatric patients</article-title>. <source>Pediatrics</source>. <year>2004</year>;<volume>113</volume>:<fpage>1820</fpage>-<lpage>1824</lpage>.</citation>
</ref>
<ref id="bibr17-0194599812473237">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jeal</surname><given-names>W</given-names></name>
<name><surname>Faulds</surname><given-names>D</given-names></name>
</person-group>. <article-title>Triamcinolone acetonide: a review of its pharmacological properties and therapeutic efficacy in the management of allergic rhinitis</article-title>. <source>Drugs</source>. <year>1997</year>;<volume>53</volume>:<fpage>257</fpage>.</citation>
</ref>
<ref id="bibr18-0194599812473237">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Khanna</surname><given-names>J</given-names></name>
<name><surname>Andrade</surname><given-names>N</given-names></name>
</person-group>. <article-title>Oral submucous fibrosis: a new concept in surgical management: report of 100 cases</article-title>. <source>Int J Oral Maxillofac Surg</source>. <year>1995</year>;<volume>24</volume>:<fpage>433</fpage>-<lpage>439</lpage>.</citation>
</ref>
<ref id="bibr19-0194599812473237">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lai</surname><given-names>D</given-names></name>
<name><surname>Chen</surname><given-names>H</given-names></name>
<name><surname>Lin</surname><given-names>L</given-names></name>
<name><surname>Huang</surname><given-names>YL</given-names></name>
<name><surname>Tsai</surname><given-names>CC</given-names></name>
</person-group>. <article-title>Clinical evaluation of different treatment methods for oral submucous fibrosis: a 10-year experience with 150 cases</article-title>. <source>J Oral Pathol Med</source>. <year>1995</year>;<volume>24</volume>:<fpage>402</fpage>-<lpage>406</lpage>.</citation>
</ref>
<ref id="bibr20-0194599812473237">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kermer</surname><given-names>C</given-names></name>
<name><surname>Millesi</surname><given-names>W</given-names></name>
<name><surname>Watzke</surname><given-names>I</given-names></name>
</person-group>. <article-title>Local injection of corticosteroids for central giant cell granuloma: a case report</article-title>. <source>Int J Oral Maxillofac Surg</source>. <year>1994</year>;<volume>23</volume>:<fpage>366</fpage>-<lpage>368</lpage>.</citation>
</ref>
<ref id="bibr21-0194599812473237">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Haddad</surname><given-names>IK</given-names></name>
</person-group>. <article-title>Temporomandibular joint osteoarthrosis</article-title>. <source>Saudi Med J</source>. <year>2000</year>;<volume>21</volume>:<fpage>675</fpage>-<lpage>679</lpage>.</citation>
</ref>
<ref id="bibr22-0194599812473237">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rajeevan</surname><given-names>N</given-names></name>
<name><surname>Soumithran</surname><given-names>C</given-names></name>
</person-group>. <article-title>Intralesional corticosteroid injection for central giant cell granuloma: a case report</article-title>. <source>Int J Oral Maxillofac Surg</source>. <year>1998</year>;<volume>27</volume>:<fpage>303</fpage>-<lpage>304</lpage>.</citation>
</ref>
<ref id="bibr23-0194599812473237">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kurtz</surname><given-names>M</given-names></name>
<name><surname>Mesa</surname><given-names>M</given-names></name>
<name><surname>Alberto</surname><given-names>P</given-names></name>
</person-group>. <article-title>Treatment of a central giant cell lesion of the mandible with intralesional glucocorticosteroids</article-title>. <source>Oral Surg Oral Med Oral Pathol Oral Radiol Endod</source>. <year>2001</year>;<volume>91</volume>:<fpage>636</fpage>-<lpage>637</lpage>.</citation>
</ref>
<ref id="bibr24-0194599812473237">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Xia</surname><given-names>J</given-names></name>
<name><surname>Li</surname><given-names>C</given-names></name>
<name><surname>Hong</surname><given-names>Y</given-names></name>
<name><surname>Yang</surname><given-names>L</given-names></name>
<name><surname>Huang</surname><given-names>Y</given-names></name>
<name><surname>Cheng</surname><given-names>B</given-names></name>
</person-group>. <article-title>Short-term clinical evaluation of intralesional triamcinolone acetonide injection for ulcerative oral lichen planus</article-title>. <source>J Oral Pathol Med</source>. <year>2006</year>;<volume>35</volume>:<fpage>327</fpage>-<lpage>331</lpage>.</citation>
</ref>
<ref id="bibr25-0194599812473237">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Xiong</surname><given-names>C</given-names></name>
<name><surname>Li</surname><given-names>Q</given-names></name>
<name><surname>Lin</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>The efficacy of topical intralesional BCG-PSN injection in the treatment of erosive oral lichen planus: a randomized controlled trial</article-title>. <source>J Oral Pathol Med</source>. <year>2009</year>;<volume>38</volume>:<fpage>551</fpage>-<lpage>558</lpage>.</citation>
</ref>
<ref id="bibr26-0194599812473237">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Farhi</surname><given-names>D</given-names></name>
<name><surname>Dupin</surname><given-names>N</given-names></name>
</person-group>. <article-title>Pathophysiology, etiologic factors, and clinical management of oral lichen planus, part I: facts and controversies</article-title>. <source>Clin Dermatol</source>. <year>2010</year>;<volume>28</volume>:<fpage>100</fpage>-<lpage>108</lpage>.</citation>
</ref>
<ref id="bibr27-0194599812473237">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ungphaiboon</surname><given-names>S</given-names></name>
<name><surname>Nittayananta</surname><given-names>W</given-names></name>
<name><surname>Vuddhakul</surname><given-names>V</given-names></name>
<etal/>
</person-group>. <article-title>Formulation and efficacy of triamcinolone acetonide mouthwash for treating oral lichen planus</article-title>. <source>Am J Health Syst Pharm</source>. <year>2005</year>;<volume>62</volume>:<fpage>485</fpage>-<lpage>491</lpage>.</citation>
</ref>
<ref id="bibr28-0194599812473237">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rhodus</surname><given-names>N</given-names></name>
<name><surname>Cheng</surname><given-names>B</given-names></name>
<name><surname>Bowles</surname><given-names>W</given-names></name>
<name><surname>Myers</surname><given-names>S</given-names></name>
<name><surname>Miller</surname><given-names>L</given-names></name>
<name><surname>Ondrey</surname><given-names>F</given-names></name>
</person-group>. <article-title>Proinflammatory cytokine levels in saliva before and after treatment of (erosive) oral lichen planus with dexamethasone</article-title>. <source>Oral Dis</source>. <year>2006</year>;<volume>12</volume>:<fpage>112</fpage>-<lpage>116</lpage>.</citation>
</ref>
<ref id="bibr29-0194599812473237">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hegarty</surname><given-names>A</given-names></name>
<name><surname>McGrath</surname><given-names>C</given-names></name>
<name><surname>Hodgson</surname><given-names>TA</given-names></name>
<name><surname>Porter</surname><given-names>SR</given-names></name>
</person-group>. <article-title>Patient-centred outcome measures in oral medicine: are they valid and reliable?</article-title> <source>Int J Oral Maxillofac Surg</source>. <year>2002</year>;<volume>31</volume>:<fpage>670</fpage>-<lpage>674</lpage>.</citation>
</ref>
<ref id="bibr30-0194599812473237">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>González-García</surname><given-names>A</given-names></name>
<name><surname>Diniz-Freitas</surname><given-names>M</given-names></name>
<name><surname>Gándara-Vila</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>Triamcinolone acetonide mouth rinses for treatment of erosive oral lichen planus: efficacy and risk of fungal over-infection</article-title>. <source>Oral Dis</source>. <year>2006</year>;<volume>12</volume>:<fpage>559</fpage>-<lpage>565</lpage>.</citation>
</ref>
<ref id="bibr31-0194599812473237">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rödström</surname><given-names>P</given-names></name>
<name><surname>Hakeberg</surname><given-names>M</given-names></name>
<name><surname>Jontell</surname><given-names>M</given-names></name>
<name><surname>Nordin</surname><given-names>P</given-names></name>
</person-group>. <article-title>Erosive oral lichen planus treated with clobetasol propionate and triamcinolone acetonide in Orabase: a double-blind clinical trial</article-title>. <source>J Dermatolog Treat</source>. <year>1994</year>;<volume>5</volume>:<fpage>7</fpage>-<lpage>10</lpage>.</citation>
</ref>
<ref id="bibr32-0194599812473237">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hegarty</surname><given-names>AM</given-names></name>
<name><surname>Hodgson</surname><given-names>TA</given-names></name>
<name><surname>Lewsey</surname><given-names>JD</given-names></name>
<name><surname>Porter</surname><given-names>SR</given-names></name>
</person-group>. <article-title>Fluticasone propionate spray and betamethasone sodium phosphate mouthrinse: a randomized crossover study for the treatment of symptomatic oral lichen planus</article-title>. <source>J Am Acad Dermatol</source>. <year>2002</year>;<volume>47</volume>:<fpage>271</fpage>-<lpage>279</lpage>.</citation>
</ref>
<ref id="bibr33-0194599812473237">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ghabanchi</surname><given-names>J</given-names></name>
<name><surname>Najafi</surname><given-names>RB</given-names></name>
<name><surname>Haghnegahdar</surname><given-names>S</given-names></name>
</person-group>. <article-title>Treatment of oral inflammatory diseases with a new mucoadhesive prednisolone tablet versus triamcinolone acetonide paste</article-title>. <source>Iran Red Crescent Med J</source>. <year>2009</year>;<volume>11</volume>:<fpage>155</fpage>-<lpage>159</lpage>.</citation>
</ref>
<ref id="bibr34-0194599812473237">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Carbone</surname><given-names>M</given-names></name>
<name><surname>Arduino</surname><given-names>P</given-names></name>
<name><surname>Carrozzo</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Topical clobetasol in the treatment of atrophic-erosive oral lichen planus: a randomized controlled trial to compare two preparations with different concentrations</article-title>. <source>J Oral Pathol Med</source>. <year>2009</year>;<volume>38</volume>:<fpage>227</fpage>-<lpage>233</lpage>.</citation>
</ref>
<ref id="bibr35-0194599812473237">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Campisi</surname><given-names>G</given-names></name>
<name><surname>Giandalia</surname><given-names>G</given-names></name>
<name><surname>De Caro</surname><given-names>V</given-names></name>
<name><surname>Di Liberto</surname><given-names>C</given-names></name>
<name><surname>Aricò</surname><given-names>P</given-names></name>
<name><surname>Giannola</surname><given-names>LI</given-names></name>
</person-group>. <article-title>A new delivery system of clobetasol-17-propionate (lipid-loaded microspheres 0.025%) compared with a conventional formulation (lipophilic ointment in a hydrophilic phase 0.025%) in topical treatment of atrophic/erosive oral lichen planus: a phase IV, randomized, observer-blinded, parallel group clinical trial</article-title>. <source>Br J Dermatol</source>. <year>2004</year>;<volume>150</volume>:<fpage>984</fpage>-<lpage>990</lpage>.</citation>
</ref>
<ref id="bibr36-0194599812473237">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Levin</surname><given-names>C</given-names></name>
<name><surname>Maibach</surname><given-names>HI</given-names></name>
</person-group>. <article-title>Topical corticosteroid-induced adrenocortical insufficiency: clinical implications</article-title>. <source>Am J Clin Dermatol</source>. <year>2002</year>;<volume>3</volume>:<fpage>141</fpage>-<lpage>147</lpage>.</citation>
</ref>
<ref id="bibr37-0194599812473237">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gilbertson</surname><given-names>EO</given-names></name>
<name><surname>Spellman</surname><given-names>MC</given-names></name>
<name><surname>Piacquadio</surname><given-names>DJ</given-names></name>
<name><surname>Mulford</surname><given-names>MI</given-names></name>
</person-group>. <article-title>Super potent topical corticosteroid use associated with adrenal suppression: clinical considerations</article-title>. <source>J Am Acad Dermatol</source>. <year>1998</year>;<volume>38</volume>:<fpage>318</fpage>-<lpage>321</lpage>.</citation>
</ref>
<ref id="bibr38-0194599812473237">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thongprasom</surname><given-names>K</given-names></name>
<name><surname>Luangjarmekorn</surname><given-names>L</given-names></name>
<name><surname>Sererat</surname><given-names>T</given-names></name>
<name><surname>Taweesap</surname><given-names>W</given-names></name>
</person-group>. <article-title>Relative efficacy of fluocinolone acetonide compared with triamcinolone acetonide in treatment of oral lichen planus</article-title>. <source>J Oral Pathol Med</source>. <year>1992</year>;<volume>21</volume>:<fpage>456</fpage>-<lpage>458</lpage>.</citation>
</ref>
<ref id="bibr39-0194599812473237">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lozada-Nur</surname><given-names>F</given-names></name>
<name><surname>Miranda</surname><given-names>C</given-names></name>
<name><surname>Maliksi</surname><given-names>R</given-names></name>
</person-group>. <article-title>Double-blind clinical trial of 0.05% clobetasol proprionate ointment in orabase and 0.05% fluocinonide ointment in orabase in the treatment of patients with oral vesiculoerosive diseases</article-title>. <source>Oral Surg Oral Med Oral Pathol</source>. <year>1994</year>;<volume>77</volume>:<fpage>598</fpage>-<lpage>604</lpage>.</citation>
</ref>
<ref id="bibr40-0194599812473237">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gonzalez-Moles</surname><given-names>MA</given-names></name>
<name><surname>Morales</surname><given-names>P</given-names></name>
<name><surname>Rodriguez-Archilla</surname><given-names>A</given-names></name>
<name><surname>Isabel</surname><given-names>IR</given-names></name>
<name><surname>Gonzalez-Moles</surname><given-names>S</given-names></name>
</person-group>. <article-title>Treatment of severe chronic oral erosive lesions with clobetasol propionate in aqueous solution</article-title>. <source>Oral Surg Oral Med Oral Pathol Oral Radiol Endod</source>. <year>2002</year>;<volume>93</volume>:<fpage>264</fpage>-<lpage>270</lpage>.</citation>
</ref>
<ref id="bibr41-0194599812473237">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cribier</surname><given-names>B</given-names></name>
<name><surname>Frances</surname><given-names>C</given-names></name>
<name><surname>Chosidow</surname><given-names>O</given-names></name>
</person-group>. <article-title>Treatment of lichen planus: an evidence-based medicine analysis of efficacy</article-title>. <source>Arch Dermatol</source>. <year>1998</year>;<volume>134</volume>:<fpage>1521</fpage>.</citation>
</ref>
<ref id="bibr42-0194599812473237">
<label>42.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cawson</surname><given-names>R</given-names></name>
</person-group>. <article-title>Treatment of oral lichen planus with betamethasone</article-title>. <source>BMJ</source>. <year>1968</year>;<volume>1</volume>:<fpage>86</fpage>-<lpage>89</lpage>.</citation>
</ref>
<ref id="bibr43-0194599812473237">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Locker</surname><given-names>D</given-names></name>
<name><surname>Jokovic</surname><given-names>A</given-names></name>
<name><surname>Clarke</surname><given-names>M</given-names></name>
</person-group>. <article-title>Assessing the responsiveness of measures of oral health-related quality of life</article-title>. <source>Community Dent Oral Epidemiol</source>. <year>2004</year>;<volume>32</volume>:<fpage>10</fpage>-<lpage>18</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>